A5069682738- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- Prostate Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Urinary and Genital Oncology Studies
- Gastrointestinal Tumor Research and Treatment
- Pharmaceutical Economics and Policy
- Multiple and Secondary Primary Cancers
- Lung Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Statistical Methods in Clinical Trials
- Lung Cancer Research Studies
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Management of metastatic bone disease
Johnson & Johnson (Italy)
2024
Janssen (Italy)
2019-2023
Janssen (Belgium)
2023
Osi is a 3rd-generation EGFR TKI indicated for 1st- (1L) and 2nd-line (2L) treatment of adult pts with advanced NSCLC common mutations (cEGFRm; exon 19 deletions [ex19del] or 21 L858R mutations). Not all patients benefit from osi Tx, most eventually develop resistance. There are currently few approved targeted Tx cEGFRm NSCLC. Here we characterise pt profiles to describe the population existing unmet medical need. This retrospective study uses data Epidemiological Strategy Medical Economics...
Understanding the distribution of prostate cancer (PC) at various clinical stages disease is utmost importance to quantify care needs patients and adequately plan health services. The aim this analysis thus provide a model-based estimation number prevalent PC different in Italian setting. A simulation model patient transitions was constructed on yearly basis using data obtained through literature review incidence, prevalence, progression mortality PC, with specific focus stage. total 462,570...
Abstract Objectives The management of non-metastatic castration-resistant prostate cancer (nmCRPC) is rapidly evolving; however, little known about the direct healthcare costs nmCRPC. We aimed to estimate cost-of-illness (COI) nmCRPC from Italian National Health Service perspective. Methods Structured, individual qualitative interviews were carried out with clinical experts identify what resources are consumed in practice. To collect quantitative estimates resource consumption, a structured...
Introduction Different value frameworks (VFs) have been proposed in order to translate available evidence on risk-benefit profiles of new treatments into Pricing & Reimbursement (P&R) decisions. However limited is the impact their implementation. It's relevant distinguish among VFs by scientific societies and providers, which usually are applicable all treatments, elaborated regulatory agencies health technology assessment (HTA), focused specific therapeutic areas. Such heterogeneity...
157 Background: Apalutamide (Apa) delays the onset of metastases and extends survival in nmCRPC. However, benefit subsequent therapy for metastatic castration resistant prostate cancer (mCRPC) following progression on Apa remains inadequately explored. Methods: A post-hoc analysis SPARTAN, a randomized phase III (NCT01946204), double-blind, placebo-controlled trial with treatment men nmCRPC was undertaken order to assess impact post-protocol treatment. Patients included this were SPARTAN...
Health state valuation and diagnostic-therapeutic pathways at the junction between non-metastatic metastatic castration-resistant prostate cancer (CRPC) are not well documented. We aimed at: (i) estimating disability weights (DWs) for health states across a continuum of disease from asymptomatic (nmCRPC) to symptomatic (mCRPC); (ii) mapping pathway nmCRPC in Italy.Structured qualitative interviews were performed with clinical experts gather information on pathway. An online survey was...